Meet our team at A3P BioProduction International Congress

The purpose of the actual study was to evaluate the coupling of three orthogonal technologies, used either in flow-through or in frontal mode and without any pH or conductivity adjustment, to intermediate purify and polish a mAb post-viral inactivation. Activated carbon, coupled with cationic Eshmuno^® CPX and anionic Eshmuno^® Q resins all set inline, generated promising results and significant improvements in terms time, cost and footprint reduction, as well as increased productivity.

A new USP scale up strategy will be highlighted during this presentation. For further upstream processes, a scale transfer involving a better understanding of our production equipment will be used. Oxygen mass transfer models have been created for all the bioreactors used at Merck Biodevelopment (at both process development and production scales) in order to be able to maintain this parameter constant. First results obtained at 200L scale with this more rational and controlled scale up approach will be shared. To conclude, an improvement of CO₂ stripping strategy will be discussed.